Life
Science

Physics & Engineering

 

Sortieren nach: Datum | Licensing Manager
Home › Technology Offers
Es wurden 5 Technologieangebote gefunden

Mixing Chamber for Constant Bead Concentrations in a Suspension


29.10.2009 | Ref.Nr. 05082
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Mixing chamber

We offer a novel automated eight well mixing chamber that guarantees a uniform distribution of micro particles in a suspension for every single measurement. The chamber construction allows their use in combination with liquid-handling-roboters, which are common in High-Throughout-Screening. The constant distribution of the micro particles is achieved by creating a turbulent, quasistatic state in the suspension. The use of the chamber allows the running of standardized processes and therewith to more easily compare measuring results in proteome analysis.

IP Rights
German patent application was filed in September 2007.
International patent application was filed in September 2008.

Origin

Charité – Universitätsmedizin Berlin
Rheinisch-Westfälische Technische Hochschule Aachen (RWTH)
Application Area:
Functional proteome analysis, Enzyme analysis by mass spectrometry
Development Stage: Prototype
Schlagworte: Mixing Chamber,
Weitere Kategorien: Research Tools, Pharma & Biotech
Bild des Benutzers Dr. Janin Hofmann
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Suitable Industry: Chemicals, Pharmaceuticals, Diagnostics
Benefits:
  • Compatible with liquid-handling-roboters that are common in High-Throughput-screening
  • Mixing chamber can be incorporated into existing high-throughput equipmen
  • Standardized process measuring results are easy to compare
  • Functional prototype exists

miRNA Maturation Assay – Screening Tool for Specific miRNA Maturation Inhibitors


13.02.2009 | Ref.Nr. 07054
Download as PDF PDF Download Share
Life Science › Pharma&Biotech › Oncology

The micro RNA maturation assay offers the opportunity to screen for small molecules influencing the dicer-mediated maturation process of miRNAs. miRNAs are molecules regulating the expression of around 30% of the human genes. The dicer protein catalyses the last step of maturation from pre-miRNA to active miRNAs. If the binding of the dicer to the individual pre-miRNA is disturbed the miRNA remains in the immature state and is, therefore, inactive.

Molecules that interfere specifically in the dicer-pre-miRNA interaction can be used as new therapeutic agents to modulate gene regulation. The new assay allows the screening for molecules that prevent the dicer binding to pre-miRNAs. As miRNAs are regulators in metabolic pathways they are involved also in many diseases. Specific miRNA maturation inhibitors will have the potential to be used as new therapeutic approaches for diseases like cancer, diabetes, or viral infections. The micro RNA maturation assay is based on microtiter plate technology and real-time fluorescence to allow high throughput screening of compound libraries.

 

IP Rights
US patent application filed on July, 18, 2008 with priority on 20/07/2007.

Origin
The development was made by Humboldt-Universität zu Berlin (Germany).

 

Application Area:
Oncology, infectiology, Research Tool
Development Stage: In vitro
Type of Collaboration: License
Schlagworte: High-Throughput Screening, Maturation Assay, Maturation Inhibitor, Micro-RNA, pre-miRNA,
Weitere Kategorien: Life Science, Research Tools, Pharma & Biotech, Oncology
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:

  • Assay based on micro titer plate and real-time fluorescence allows for high throughput screening of compounds which specifically inhibit maturation of one specific miRNA
  • Assay is easy to handle, fast and cost-effective
  • Can be extended to any known miRNA
  • Alternative application: Assay for RNA characterization

Typ I Interferon receptor deficient mice for analysing immunological diseases


11.02.2009 | Ref.Nr. 04130
Download as PDF PDF Download Share
Life Science › Pharma&Biotech

Interferons take in a vital role in the natural response on viral infection. In particular, type I interferon (IFN-I) is the focus of interest in the development of new therapeutic approaches for example in the fields of immunology, tumor diseases, multiple sclerosis and sepsis. So far available transgenic mice with a complete knock-out of the IFN-I receptor (IFNAR) have been generated on the background of the mouse type SV129.

This type, however, is only restrictedly suitable for studies on infectious diseases, multiple sclerosis and sepsis. Moreover, most of the tumors used in tumor models have been isolated from another mouse type, C57BL/6. 

The presented  INFARKO mouse is an essential tool in the research of immunological diseases.  It is congenic on the C57BL/6 background and carries a ubiquitous deletion of  IFNAR allowing you unlimited investigations into the role of IFNAR in every tissue, cell type, stage of development or in the response on exogenous stimuli.

 

IP Rights
German Utility Model for IFNARKO Mouse: No. 202004019129.6

Origin
Breeding took place at the Paul-Ehrlich-Institute (PEI) following GLP standard.

 

Application Area:
Pharmaceutical research
Development Stage: Product, Prototyp
Type of Collaboration: License
Schlagworte: IFN-1 Receptor, Knock-Out, Mouse Model, Therapeutic,
Weitere Kategorien: Life Science, Research Tools, Pharma & Biotech
Bild des Benutzers Rafaela Kunz
Licensing Manager: Rafaela Kunz
T +49 30 2125 4825
F +49 30 2125 4822
rafaela.kunz@ipal.de
Market Potential: Worldwide
Benefits:
  • Homozygous mouse with a ubiquitously inactivated type I interferon receptor (INFARKO)
  • INFARKO mouse is congenic (20x crossed back) on the C57BL/6 background (tumor mice)

Controlled Activation of LINE-1 Retrotransposons in Mammals


07.11.2008 | Ref.Nr. 07059
Download as PDF PDF Download Share
Life Science › Pharma&Biotech › Genetic engineering

Retrotransposons comprise a large group of mobile genetic elements in eucaryotic genomes. Retrotransposons are transcribed, the resulting mRNA is reverse trancribed and the cDNA is reintegrated into the genome at different genomic sites thereby duplicating the element. LINE-1 (Long Interspersed element-1) elements represent the major class of mammalian non-LTR (long terminal repeat) retrotransposons which are covering 35 % of the human genome.

LINE-1 is the only autonomous non-LTR retrotransposon in the human genome because it is coding for the protein machinery required for its mobilization. LINE-1 retrotransposition events can disrupt gene expression and can cause genetic disorders or cancer such as hemophilia A or breast cancer.
For the first time, a system has been developed which allows inducible, controlled and conditional expression and retrotransposition of non-LTR retrotransposons, in particular LINE-1 elements in mammals (cell culture and in vivo).
The LINE-element is tagged with a reporter gene cassette and set under control of a tetracycline/doxycycline-inducible promoter. The modified LINE element can be used as a tool for insertion mutagenesis or, tagged with a therapeutical gene, as a gene delivery system in gene therapy. Furthermore oncogenes, which depend on LINE-1 transposition in somatic cells at different point of time during embryonic development can be identified by gene trapping in specific tissues or cell types.

 

IP Rights
An European patent application (EP 07 021 311.1) has been filed on October, 31, 2007.  A PCT has been applied.

Origin
This technology has been developed at the Paul-Ehrlich Institut, Langen.

Application Area:
Research tools, Gene therapy
Development Stage: Prototyp
Type of Collaboration: License
Schlagworte: Cell, DNA, Genetic, LINE-1, non-LTR, Retrotransposons,
Weitere Kategorien: Life Science, Research Tools, Pharma & Biotech, Genetic engineering
Bild des Benutzers Dr. Janin Hofmann
Licensing Manager: Dr. Janin Hofmann
T +49 30 2125 4828
F +49 30 2125 4822
janin.hofmann@ipal.de
Market Potential: Worldwide
Benefits:
  • Conditional activation of LINE-1 retrotransposition in mammalian organisms
  • Inducible non-LTR retrotransposons as novel tools for gene delivery
  • Reporter cassette enables monitoring, quantification, localization, isolation and characterization of genomic de- novo retrotransposition events.
  • Proof-of-principle (Tet/Dox-On/Off-System) demonstrated in M2-HeLa cells.

Polygenic Mouse Model for Juvenile Obesity Research


30.10.2008 | Ref.Nr. 09001
Download as PDF PDF Download Share
Life Science › Pharma&Biotech › Metabolism

We offer a set of well-characterized polygenic mouse models that allow the test of drugs for weight loss and the targeted search for genetic factors influencing fat deposition. We offer two animal groups: The Berlin Fat Mouse (BFM) outbred population and the Berlin Fat Mouse Inbred 860 (BFMI860) strain.

BFM has been selected for high fatness and low protein content from a base population of animals bought in several Berlin pet shops. BFMI860 is an inbred derivate of BFM that has been generated by repeated matings of most obese BFM full-sibs after 58 generations of selection. BFM and BFMI860 develop extreme body weight with high body fat mass, but only marginal increased body lean mass. The phenotype is visible already at a very early age. Highest weight gain occurs between 6 and 10 weeks. At standard diet, the adult animals of the BFMI860 strain had a body fat percentage of 22 to 30% in males and 28 to 37% in females compared to 6% in wildtype mice. The animals respond to high fat diet with further increase of adiposity. BFMI860 mice show several features of the metabolic syndrome. Consistent with the high genetic variability, BFM animals have a higher variability in the fat percentage and related phenotypes than BFMI860.


Origin
The development was made by the Humboldt-Universität zu Berlin.

Application Area:
Metabolism, Pharmaceutical Research
Development Stage: Product
Type of Collaboration: License
Schlagworte: Fat, Obesity, Polygenic Mouse Model,
Weitere Kategorien: Life Science, Nutrition, Research Tools, Pharma & Biotech, Metabolism
Bild des Benutzers Dr. Bettina Büttner
Licensing Manager: Dr. Bettina Büttner
T +49 30 2125 4835
F +49 30 2125 4822
bettina.buettner@ipal.de
Market Potential: Worldwide
Benefits:

The BFM population and the BFMI860 mouse strain are excellent models to study

  • development of obesity and related traits
  • response to different diets
  • response to drugs inhibiting obesity
  • genes regulated after treatment of obesity or by different diets
  • gene interaction between obesity genes and disease genes related to obesity